410 related articles for article (PubMed ID: 27122198)
1. Investigational therapies for renal disease-induced anemia.
Schmid H; Jelkmann W
Expert Opin Investig Drugs; 2016 Aug; 25(8):901-16. PubMed ID: 27122198
[TBL] [Abstract][Full Text] [Related]
2. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
[TBL] [Abstract][Full Text] [Related]
3. Will there still be a role for the originator erythropoiesis-simulating agents after the biosimilars and the hypoxia-inducible factor stabilizers approval?
Locatelli F; Del Vecchio L
Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):339-344. PubMed ID: 29846220
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a paradigm shift for treatment of anemia in chronic kidney disease?
Souza E; Cho KH; Harris ST; Flindt NR; Watt RK; Pai AB
Expert Opin Investig Drugs; 2020 Aug; 29(8):831-844. PubMed ID: 32476498
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for the treatment of kidney disease-induced anemia.
Malyszko J; Malyszko JS
Expert Opin Emerg Drugs; 2016 Sep; 21(3):315-30. PubMed ID: 27537859
[TBL] [Abstract][Full Text] [Related]
6. Current and future chemical therapies for treating anaemia in chronic kidney disease.
Locatelli F; Del Vecchio L; Luise MC
Expert Opin Pharmacother; 2017 Jun; 18(8):781-788. PubMed ID: 28443351
[TBL] [Abstract][Full Text] [Related]
7. New Treatment Approaches for the Anemia of CKD.
Bonomini M; Del Vecchio L; Sirolli V; Locatelli F
Am J Kidney Dis; 2016 Jan; 67(1):133-42. PubMed ID: 26372086
[TBL] [Abstract][Full Text] [Related]
8. Peginesatide for the treatment of renal disease-induced anemia.
Schmid H
Expert Opin Pharmacother; 2013 May; 14(7):937-48. PubMed ID: 23506424
[TBL] [Abstract][Full Text] [Related]
9. Experimental and investigational therapies for chemotherapy-induced anemia.
Testa U; Castelli G; Elvira P
Expert Opin Investig Drugs; 2015; 24(11):1433-45. PubMed ID: 26359222
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients.
Chen H; Cheng Q; Wang J; Zhao X; Zhu S
J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
Mima A
Eur J Pharmacol; 2021 Dec; 912():174583. PubMed ID: 34678238
[TBL] [Abstract][Full Text] [Related]
12. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
13. Anemia in chronic kidney disease.
Atkinson MA; Warady BA
Pediatr Nephrol; 2018 Feb; 33(2):227-238. PubMed ID: 28412770
[TBL] [Abstract][Full Text] [Related]
14. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Drug Saf; 2016 Aug; 15(8):1021-30. PubMed ID: 27149639
[TBL] [Abstract][Full Text] [Related]
15. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis.
Rainville N; Jachimowicz E; Wojchowski DM
Expert Opin Ther Targets; 2016; 20(3):287-301. PubMed ID: 26419263
[TBL] [Abstract][Full Text] [Related]
16. Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.
Weir MR
Am J Nephrol; 2021; 52(6):450-466. PubMed ID: 34280923
[TBL] [Abstract][Full Text] [Related]
17. Roxadustat in the treatment of anaemia in chronic kidney disease.
Del Vecchio L; Locatelli F
Expert Opin Investig Drugs; 2018 Jan; 27(1):125-133. PubMed ID: 29254377
[TBL] [Abstract][Full Text] [Related]
18. Iron Metabolism in Chronic Kidney Disease Patients.
Honda H; Hosaka N; Ganz T; Shibata T
Contrib Nephrol; 2019; 198():103-111. PubMed ID: 30991401
[TBL] [Abstract][Full Text] [Related]
19. Novel Masters of Erythropoiesis: Hypoxia Inducible Factors and Recent Advances in Anemia of Renal Disease.
Solak Y; Cetiner M; Siriopol D; Tarim K; Afsar B; Covic A; Kanbay M
Blood Purif; 2016; 42(2):160-7. PubMed ID: 27318465
[TBL] [Abstract][Full Text] [Related]
20. Emerging drugs for treatment of anemia of chronic kidney disease.
Magwood JS; Lebby A; Chen B; Kessler S; Norris L; Bennett CL
Expert Opin Emerg Drugs; 2013 Dec; 18(4):421-9. PubMed ID: 24033253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
